Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.38 |
| ▸ | ITGAL | P20701 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 12/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 2/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807609 | 0.98 | ITGB2 (0.39) | ALDH1A1HSD17B10ITGB2ICAM1ITGAL | |
| SCHEMBL6808473 | 0.91 | ITGB2 (0.42) | ALDH1A1HSD17B10ITGB2ICAM1ITGAL | |
| SCHEMBL6808563 | 0.91 | ATM (0.39) | TACR1POLB | |
| SCHEMBL6803199 | 0.89 | ITGB1 (0.40) | ALDH1A1HSD17B10ITGB2ICAM1ITGAL | |
| SCHEMBL6807916 | 0.89 | ITGB2 (0.43) | ALDH1A1HSD17B10ITGB2ICAM1ITGAL | |
| SCHEMBL6812605 | 0.89 | ITGB2 (0.40) | ALDH1A1HSD17B10ITGB2ICAM1ITGAL | |
| SCHEMBL6812952 | 0.87 | ITGB2 (0.41) | ITGB2ICAM1ITGALITGB1ITGA4 | |
| SCHEMBL6808926 | 0.87 | MEN1 (0.42) | ALDH1A1HSD17B10ITGB1ITGA4ITGB7 | |
| SCHEMBL6807444 | 0.84 | ITGB2 (0.42) | ITGB2ICAM1ITGALITGB1ITGA4 | |
| SCHEMBL6803788 | 0.83 | ITGB2 (0.42) | ITGB2ICAM1ITGALITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | ALDH1A1 283/4885HSD17B10 3498/4885ITGB2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.